Genome-wide association study of antipsychotic induced QTc interval prolongation

QT prolongation is associated with increased risk of cardiac arrhythmias. Identifying the genetic variants that mediate antipsychotic-induced prolongation may help to minimize this risk, which might prevent the removal of efficacious drugs from the market. We performed candidate gene analysis and five drug-specific genome-wide association studies (GWASs) with 492K single-nucleotide polymorphisms to search for genetic variation mediating antipsychotic-induced QT prolongation in 738 schizophrenia patients from the Clinical Antipsychotic Trial of Intervention Effectiveness study. Our candidate gene study suggests the involvement of NOS1AP and NUBPL (P-values=1.45 × 10−05 and 2.66 × 10−13, respectively). Furthermore, our top GWAS hit achieving genome-wide significance, defined as a Q-value <0.10 (P-value=1.54 × 10−7, Q-value=0.07), located in SLC22A23, mediated the effects of quetiapine on prolongation. SLC22A23 belongs to a family of organic ion transporters that shuttle a variety of compounds, including drugs, environmental toxins and endogenous metabolites, across the cell membrane. This gene is expressed in the heart and is integral in mouse heart development. The genes mediating antipsychotic-induced QT prolongation partially overlap with the genes affecting normal QT interval variation. However, some genes may also be unique for drug-induced prolongation. This study demonstrates the potential of GWAS to discover genes and pathways that mediate antipsychotic-induced QT prolongation.

[1]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[2]  Christian Gieger,et al.  Common variants at ten loci modulate the QT interval duration in the QTSCD Study , 2009, Nature Genetics.

[3]  A. Hofman,et al.  Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. , 2007, Circulation.

[4]  A. McCallion,et al.  Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes. , 2008, The Journal of clinical investigation.

[5]  G. Breithardt,et al.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.

[6]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Viskin,et al.  Long QT syndrome caused by noncardiac drugs. , 2003, Progress in cardiovascular diseases.

[8]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet , 1996 .

[9]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[10]  S. Dudoit,et al.  Resampling-based multiple testing for microarray data analysis , 2003 .

[11]  S. Viskin,et al.  Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors , 2003, Medicine.

[12]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[13]  Daniel E. Adkins,et al.  A systematic method for estimating individual responses to treatment with antipsychotics in CATIE , 2009, Schizophrenia Research.

[14]  L. Kirk,et al.  [Treatment of schizophrenia]. , 1971, Ugeskrift for laeger.

[15]  Patrick F Sullivan,et al.  False discoveries and models for gene discovery. , 2003, Trends in genetics : TIG.

[16]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[17]  Christian Gieger,et al.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization , 2006, Nature Genetics.

[18]  John D. Storey The positive false discovery rate: a Bayesian interpretation and the q-value , 2003 .

[19]  Robert Fredriksson,et al.  Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. , 2007, Genomics.

[20]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[21]  M. Kamalesh,et al.  Effect of risperidone on QT interval and QT dispersion in the elderly. , 2000, Heart disease.

[22]  J. Lieberman,et al.  Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2008, Molecular Psychiatry.

[23]  Johan van der Lei,et al.  Antipsychotics and the risk of sudden cardiac death. , 2004, Archives of internal medicine.

[24]  Risto Lehtonen,et al.  Multilevel Statistical Models , 2005 .

[25]  M. Tobin,et al.  Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. , 2008, International journal of epidemiology.

[26]  D. M. Taylor,et al.  Antipsychotics and QT prolongation , 2003, Acta psychiatrica Scandinavica.

[27]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[28]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[29]  Vladimir I. Vladimirov,et al.  Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects , 2010, Biological Psychiatry.

[30]  Vladimir I. Vladimirov,et al.  Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics , 2009, Molecular Psychiatry.

[31]  A. Chakravarti,et al.  Associations between Genetic Variants in the NOS1AP (CAPON) Gene and Cardiac Repolarization in the Old Order Amish , 2007, Human Heredity.

[32]  H. Koepsell,et al.  The SLC22 drug transporter family , 2004, Pflügers Archiv.

[33]  M. Polymeropoulos,et al.  Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia , 2009, Molecular Psychiatry.

[34]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[35]  J. Lieberman,et al.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. , 2003, Schizophrenia bulletin.

[36]  Karl J. Friston,et al.  Variance Components , 2003 .

[37]  József Bukszár,et al.  Estimating the posterior probability that genome-wide association findings are true or false , 2009, Bioinform..

[38]  Jan A. Kors,et al.  Common NOS1AP Variants Are Associated With a Prolonged QTc Interval in the Rotterdam Study , 2007 .

[39]  E. Marbán,et al.  CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart , 2008, Proceedings of the National Academy of Sciences.

[40]  S. Marder,et al.  Psychopharmacologic treatment of schizophrenia. , 1993, Schizophrenia bulletin.

[41]  Thomas Lumley,et al.  Common variants at ten loci influence QT interval duration in the QTGEN Study , 2009, Nature Genetics.